Mylan shares jump on EpiPen agreement; bond offerings surge; Kenon suffers in the second quarter; stocks inch up.
Platform will monitor and analyze key symptoms of neurodegenerative disease that impact daily living.
EpiPen's list price has soared from less than $100 when Mylan acquired the product in 2007, to more than $600 now, sparking outrage. Without strong competitors, Mylan's EpiPen still holds an estimated 94 percent market share.
Amid win against Teva, Mylan caves in to pressure and offers EpiPen discount | Ethiopia says Israel Chemicals owes $55 million in taxes on potash project | Pharma woes weigh on Tel Aviv shares
Drug maker beats analysts’ estimates for earnings and revenues as Copxone sales rise.
Anda, the fourth-largest U.S. distributor of generic pharmaceuticals, is on track to earn $1.5 billion in third-party net revenue and 15 cents in earnings per share.
Federal Trade Commission clears deal after Israeli drug maker agrees to sell 79 generic drugs to rival firms.
Israel-based pharmaceutical company announced it priced a debt offering to help fund acquisition after previously saying it planned to sell $22 billion of bonds.
The pharmaceutical giant's announcement sent shares up 2 percent in after-hours trading.
Migdal Insurance buys NIS 900 million of mortgages from Mizrahi Tefahot | Buyer for Teva’s U.K. generic drug portfolio seen emerging in coming weeks | TASE shares fall on global growth worries.